MDXG - MiMedx Group Inc. (MDXG) Investigation: Bronstein Gewirtz & Grossman LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

NEW YORK, NY / ACCESSWIRE / January 4, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of MiMedx Group, Inc. ("MiMedx" or "the Company") (NASDAQ:MDXG). Investors who purchased MiMedx securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MDXG.

Investigation Details:

On December 29, 2023, MiMedx issued a press release announcing that "[f]ollowing a routine inspection earlier in the year, the United States Food and Drug Administration (‘FDA') took the position that one of the Company's recently-launched placental-derived tissue products - AXIOFILL - does not meet the requirements as a Section 361 product and is therefore subject to enforcement as a Section 351 product. Specifically, FDA asserts that the production of AXIOFILL involves more than ‘minimal manipulation.' The Company does not agree with FDA's position and has been actively engaged with the agency through its ‘Request For Designation' (‘RFD') process. However, on December 21, 2023, MIMEDX received a Warning Letter from FDA reiterating the agency's position on AXIOFILL." On this news, MiMedx's stock price fell $0.90 per share, or 10.26%, to close at $7.87 per share on January 2, 2024.

What's Next?

If you are aware of any facts relating to this investigation or purchased MiMedx securities, you can assist this investigation by visiting the firm's site: bgandg.com/MDXG. You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.

There is No Cost to You

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman:

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Nathanson
332-239-2660 | info@bgandg.com

SOURCE: Bronstien, Gewirtz & Grossman, LLC